Suppr超能文献

去中心化医疗体系中的多层次药物评估。意大利案例研究。

Multi-tier drugs assessment in a decentralised health care system. The Italian case-study.

机构信息

Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani, 2, 28100 Novara, Italy; Pharmaceutical Observatory, Centre for Research on Health and Social Care Management (Cergas), Università Bocconi, Milano, Via Rontgen 1, 20100 Milano, Italy.

出版信息

Health Policy. 2013 Oct;112(3):241-7. doi: 10.1016/j.healthpol.2013.06.004. Epub 2013 Jul 12.

Abstract

OBJECTIVE

To investigate the organisation and decision-making processes of regional and local therapeutic committees in Italy, as a case-study of decentralised health care systems.

METHODS

A structured questionnaire was designed, validated, and self-administered to respondents. Committee members, prioritisation, assessment process and criteria, and transparency of committees were investigated.

RESULTS

The respondents represent 100% of the 17 regional committees out of 21 regions (in 4 regions there is not any regional formulary), 88% of the 16 hospital networks and 42% of the 183 public hospitals. The assessment process appears fragmented and may take a long time: drugs inclusion into hospital formularies requires two steps in most regions (regional and local assessment). Most of the therapeutic committees are closed to industry and patients associations involvement. Prioritisation in the assessment is mostly driven by disease severity, clinical evidence, and the absence of therapeutic alternatives. Only 13 out of the 17 regional committees have a public application form for drugs inclusion into regional formulary. Regional and local committees (i) often re-assess the clinical evidence already evaluated at central level and (ii) mostly rely on comparative drug unit prices per DDD and drug budget impact. The level of transparency is quite low.

CONCLUSIONS

The Italian case-study provides useful insights into an appropriate management of multi-tier drugs assessment, which is particularly complex in decentralised health care systems, but exists also in centralised systems where drugs are assessed by local therapeutic committees. A clear definition of regulatory competences at different levels, a higher collaboration between central, regional and local actors, and increased transparency are necessary to pursue consistency between central policies on price and reimbursement and budget accountability at the regional and local levels.

摘要

目的

以意大利的区域和地方治疗委员会为案例研究,探讨分散式医疗保健系统中区域和地方治疗委员会的组织和决策过程。

方法

设计、验证并自我管理了一份结构化问卷,以调查委员会成员、优先级、评估过程和标准以及委员会的透明度。

结果

受访者代表了 21 个地区中的 17 个区域委员会(4 个地区没有区域处方集)、88%的医院网络和 42%的 183 家公立医院中的 100%。评估过程看起来支离破碎,可能需要很长时间:药物纳入医院处方集在大多数地区需要两步(区域和地方评估)。大多数治疗委员会对工业界和患者协会的参与持封闭态度。评估中的优先级主要由疾病严重程度、临床证据和缺乏治疗替代方案驱动。在 17 个区域委员会中,只有 13 个有公开的药物纳入区域处方集的申请表。区域和地方委员会(i)经常重新评估已经在中央层面评估过的临床证据,(ii)主要依赖于比较药物单位价格每 DDD 和药物预算影响。透明度水平相当低。

结论

意大利的案例研究为多层药物评估的适当管理提供了有用的见解,这在分散式医疗保健系统中特别复杂,但在中央评估药物的集中式系统中也存在,需要明确界定不同层次的监管权限,加强中央、区域和地方行为体之间的合作,提高透明度,以追求中央药品价格和报销政策与区域和地方层面预算问责制之间的一致性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验